AAAAAA
Results:
1-21
|
Results: 21
Authors:
Huitema, ADR
Mathot, RAA
Tibben, MM
Rodenhuis, S
Beijnen, JH
Citation: Adr. Huitema et al., A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide, J PHARMA PH, 28(3), 2001, pp. 211-230
Authors:
Kerbusch, T
vanPutten, JWG
Groen, HJM
Huitema, ADR
Mathot, RAA
Beijnen, JH
Citation: T. Kerbusch et al., Population pharmacokinetics of ifosfamide and its 2-and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients, CANC CHEMOT, 48(1), 2001, pp. 53-61
Authors:
van den Bongard, HJGD
Mathot, RAA
Boogerd, W
Schornagel, JH
Soesan, M
Schellens, JHM
Beijnen, JH
Citation: Hjgd. Van Den Bongard et al., Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure, CANC CHEMOT, 47(6), 2001, pp. 537-540
Authors:
Kerbusch, T
de Kraker, J
Mathot, RAA
Beijnen, JH
Citation: T. Kerbusch et al., Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease - A sparse sampling approach, CLIN PHARMA, 40(8), 2001, pp. 615-625
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals
Authors:
Koks, CHW
Crommentuyn, KML
Hoetelmans, RMW
Burger, DM
Koopmans, PP
Mathot, RAA
Mulder, JW
Meenhorst, PL
Beijnen, JH
Citation: Chw. Koks et al., The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals, BR J CL PH, 51(6), 2001, pp. 631-635
Authors:
Huitema, ADR
Mathot, RAA
Tibben, MM
Schellens, JHM
Rodenhuis, S
Beijnen, JH
Citation: Adr. Huitema et al., Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy, BR J CL PH, 51(1), 2001, pp. 61-70
Authors:
de Maat, MMR
Hoetelmans, RMW
Mathot, RAA
van Gorp, ECM
Meenhorst, PL
Mulder, JW
Beijnen, JH
Citation: Mmr. De Maat et al., Drug interaction between St John's wort and nevirapine, AIDS, 15(3), 2001, pp. 420-421
Authors:
Huitema, ADR
Mathot, RAA
Tibben, MM
Rodenhuis, S
Beijnen, JH
Citation: Adr. Huitema et al., Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen, THER DRUG M, 23(6), 2001, pp. 650-657
Authors:
Koks, CHW
Crommentuyn, KML
Hoetelmans, RMW
Mathot, RAA
Beijnen, JH
Citation: Chw. Koks et al., Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?, THER DRUG M, 23(4), 2001, pp. 449-453
Authors:
Kerbusch, T
Mathot, RAA
Keizer, HJ
Kaijser, GP
Schellens, JHM
Beijnen, JH
Citation: T. Kerbusch et al., Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites, DRUG META D, 29(7), 2001, pp. 967-975
Authors:
Kerbusch, T
Mathot, RAA
Keizer, HJ
Ouwerkerk, J
Rodenhuis, S
Schellens, JHM
Beijnen, JH
Citation: T. Kerbusch et al., Population pharmacokinetics and exploratory pharmacodynamics of ifosfamideand metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma, EUR J CL PH, 57(6-7), 2001, pp. 467-477
Authors:
Kerbusch, T
Jansen, RLH
Mathot, RAA
Huitema, ADR
Jansen, M
van Rijswijk, REN
Beijnen, JH
Citation: T. Kerbusch et al., Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin, CLIN PHARM, 70(2), 2001, pp. 132-141
Authors:
van Kesteren, C
Cvitkovic, E
Taamma, A
Lopez-Lazaro, L
Jimeno, JM
Guzman, C
Mathot, RAA
Schellens, JHM
Misset, JL
Brain, E
Hillebrand, MJX
Rosing, H
Beijnen, JH
Citation: C. Van Kesteren et al., Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study, CLIN CANC R, 6(12), 2000, pp. 4725-4732
Authors:
Huitema, ADR
Smits, KD
Mathot, RAA
Schellans, JHM
Rodenhuis, S
Beijnen, JH
Citation: Adr. Huitema et al., The clinical pharmacology of alkylating agents in high-dose chemotherapy, ANTI-CANC D, 11(7), 2000, pp. 515-533
Authors:
van den Bongard, HJGD
Mathot, RAA
Beijnen, JH
Schellens, JHM
Citation: Hjgd. Van Den Bongard et al., Pharmacokinetically guided administration of chemotherapeutic agents, CLIN PHARMA, 39(5), 2000, pp. 345-367
Authors:
Kerbusch, T
Huitema, ADR
Ouwerkerk, J
Keizer, HJ
Mathot, RAA
Schellens, JHM
Beijnen, JH
Citation: T. Kerbusch et al., Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM, BR J CL PH, 49(6), 2000, pp. 555-561
Authors:
Geus, WP
Mathot, RAA
Mulder, PGH
Lamers, CBHW
Citation: Wp. Geus et al., Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40mg during repeated oral administration in Helicobacter pylori-negative subjects, ALIM PHARM, 14(8), 2000, pp. 1057-1064
Authors:
Vermes, A
Mathot, RAA
van der Sijs, IH
Dankert, J
Guchelaar, HJ
Citation: A. Vermes et al., Population pharmacokinetics of flucytosine: Comparison and validation of three models using STS, NPEM, and NONMEM, THER DRUG M, 22(6), 2000, pp. 676-687
Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods
Authors:
Huitema, ADR
Mathot, RAA
Tibben, MM
Schellens, JHM
Rodenhuis, S
Beijnen, JH
Citation: Adr. Huitema et al., Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods, CLIN PHARM, 67(6), 2000, pp. 621-630
Authors:
van Lent-Evers, NAEM
Mathot, RAA
Geus, WP
van Hout, BA
Vinks, AATMM
Citation: Naem. Van Lent-evers et al., Impact of goal-oriented and model-based clinical pharmacokinetic dosing ofaminoglycosides on clinical outcome: A cost-effectiveness analysis, THER DRUG M, 21(1), 1999, pp. 63-73
Authors:
Mathot, RAA
Geus, WP
Citation: Raa. Mathot et Wp. Geus, Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance, CLIN PHARM, 66(2), 1999, pp. 140-151
Risultati:
1-21
|